Background: The effectiveness of reintroduction of oxaliplatin for metastatic colorectal cancer (mCRC) refractory to both oxaliplatin and irinotecan was previously reported in a single arm, open-label phase II study (RE-OPEN, Suenaga, 2015). We conducted a phase I study to determine the maximum tolerated dose (MTD) and the safety of oxalipatin plus trifluridine/tipiracil (FTD/TPI, also known as TAS-102) in patients with refractory mCRC (UMIN000015764). Methods: Three dosages of intravenous oxaliplatin (50, 65 and 85 mg/m 2 ) on days 1 and 15 and a fixed dose of FTD/TPI 35 mg/m 2 bid on days 1-5, 15-19 every 4 weeks were investigated in patients with refractory mCRC by using a 3 þ 3 design. Eligible patients had received prior oxaliplatin-based treatment that achieved a response or stable disease followed by confirmed disease progression at least 6 months before entering the study. Results: 12 patients were enrolled in the study. Characteristics of patients were as follows: median age, 62 (range, 47-68) years; male/female, 6/6; ECOG PS 0, 75%; number of prior regimens 3, 33.3%; and median oxaliplatin-free interval, 24.3 (range, 6.2-71.4) months. 3 of 6 patients of the oxaliplatin 85mg/m 2 cohort had dose-limiting toxicities (DLTs): treatment delay on 2 nd cycle 8 days due to grade 2 neutropenia or grade 2 AST/ALT increased. No DLTs were observed in the other cohorts. The median number of treatment cycles was 3 (range, 1-9): 9 patients continued the treatment until disease progression; and 3 patients discontinued due to toxicity or patient's refusal. In safety, grade 3 adverse events were neutropenia (n ¼ 3), thrombocytopenia (n ¼ 1), anorexia (n ¼ 1) and nausea (n ¼ 1). There was no evidence of allergic reaction to oxaliplatin and severe peripheral sensory neuropathy. Conclusions: According to the results of this phase I study, a combination of trifluridine/tipiracil 35 mg/m 2 bid on days 1-5, 15-19 and oxaliplatin 85 mg/m 2 on days 1 and 15 every 4 weeks could be a candidate for recommended dose of the trifluridine/tipiracilþoxaliplatin regimen in patients with refractory mCRC. Clinical trial identification: UMIN000015764 (release date,
Background: TAS-102 study was shown to have clinical activity in a large population of Japanese and Western patientswith heavily pretreated metastatic colorectal cancer, including those whose disease was refractory to fluorouracil.But we know few date of TAS-102 in daily medical practice. So we assessed efficacy and safety of TAS-102 for refractory metastatic colorectal cancer. Methods: We retrospectively reviewed the data of 86 patientswho received TAS-102 treatment in our institution between June2014 and October2017.TAS-102 (with each dose consisting of 35 mg per square meter) was administered twice daily, 5 days on and 2 days off for 2 weeks, followed by 2 weeksrest period. The regimen was repeated every 4 weeks. Results: The median age was 69 years (range, 27-87) . Performance status of 1 and 2 were 39 and 47 patients. RAS wild and mutant were 39 and 47 patients. Primary tumor site of right and left were 25 and 61 patients. All patients had received prior chemotherapy regimens containing a fluoropyrimidine, oxaliplatin, and irinotecan. 41 patients received 4 or more prior chemotherapy. Response rate and disease control rate of all were 1% and 24%. Right and left-sided of response rate were 4% and 0%. Right and left-sided of disease control rate were 32% and 19%. Median PFS was 62 days, right and left-sided were 55 and 64 days. Median OS was 216 days, right and left-sided were 262 and 200 days. OS was longer than previously reported. 40 patientsreceived subsequent chemotherapy. Adverse events were mild with 18% of Grade 4 neutropenia and 4% of Grade 3 febrile neutropenia. Conclusions: TAS-102 was active and tolerable for heavily treated refractory metastatic colorectal cancer. There were no significant difference of PFS and OS in primary tumor site.
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473P Influence of the proton pump inhibitor esomeprazole on the bioavailability of regorafenib Background: The multikinase inhibitor regorafenib (REG) is currently registered for the treatment of colorectal cancer (CRC), gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma. REG exhibits a pH-dependent solubility, and therefore acid reducing drugs such as proton pump inhibitors (PPIs, e.g. esomeprazole) might reduce REG absorption by increasing the stomach pH as was shown for many other kinase inhibitors (van Leeuwen, Lancet Oncol, 2014). We performed a randomized, 3-phase, cross-over trial to compare the exposure of REG alone to REG with esomeprazole (concomitantly or 3 hours prior to REG intake) in CRC and GIST patients. Methods: Patients were randomized into 2 sequence groups consisting of 3 phases: REG intake alone, REG with concomitant esomeprazole (for 5 days), and REG 3 hours preceded by esomeprazole (for 5 days). Pharmacokinetic (PK) blood sampling was performed at the 21 th , 49 th and 77 th day of the trial. All patients were treated with REG 120 mg at steady-state. Primary endpoint was the relative difference (RD) in geometric means for REG AUC 0-24h . A linear mixed model was used to analyze log-transformed area under the curve (AUC). For multiple testing a Bonferroni correction was applied.
Results: A total of 14 patients were evaluable for the primary endpoint. Exposure (AUC 0-24h ) to REG alone was: 55.9 mg*h/mL (CV: 40.3%). For REG with concomitant esomeprazole or with esomeprazole 3 hours prior AUC 0-24h was: 53.7 mg*h/mL (CV: 33.5%) and 53.6 mg*h/mL (CV: 42.6%) respectively. No significant differences were identified when REG alone was compared to REG with concomitant esomeprazole (RD: -3.9%, 95% CI: -20.5-16.1%, p ¼ 1.0) or REG with esomeprazole 3 hours prior (RD: -4.1%, 95% CI: -22.8-19.2%, p ¼ 1.0). Furthermore, no significant differences were observed in other PK parameters of REG and its active metabolites M-2 and M-5 (i.e. C max , T max ). Most common adverse events grade 2 were hypertension (71%), fatigue (43%) and hand foot skin reaction (36% 
